PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23521797-0	2013	Discovery of oxysterol-derived pharmacological chaperones for NPC1: implication for the existence of second sterol-binding site.	Oxysterols	13-22	NPC intracellular cholesterol transporter 1	Homo sapiens	62-66	
23521797-5	2013	These oxysterol derivatives bind to a domain of NPC1 that is different from the known N-terminal sterol-binding domain; i.e., there is an additional sterol-binding site on NPC1.	Oxysterols	6-15	NPC intracellular cholesterol transporter 1	Homo sapiens	48-52	
23521797-5	2013	These oxysterol derivatives bind to a domain of NPC1 that is different from the known N-terminal sterol-binding domain; i.e., there is an additional sterol-binding site on NPC1.	Oxysterols	6-15	NPC intracellular cholesterol transporter 1	Homo sapiens	172-176	
17989073-5	2008	Unexpectedly, we encountered NPC1 in a search for a membrane protein that binds 25-hydroxycholesterol (25-HC) and other oxysterols.	Oxysterols	120-130	NPC intracellular cholesterol transporter 1	Homo sapiens	29-33	
17989073-7	2008	We prepared recombinant human NPC1 and confirmed its ability to bind oxysterols, including those with a hydroxyl group on the 24, 25, or 27 positions.	Oxysterols	69-79	NPC intracellular cholesterol transporter 1	Homo sapiens	30-34	
17989073-13	2008	The availability of assays to measure NPC1 binding in vitro may further the understanding of ways in which oxysterols regulate intracellular lipid transport.	Oxysterols	107-117	NPC intracellular cholesterol transporter 1	Homo sapiens	38-42	
33315900-3	2020	We previously identified a series of oxysterol derivatives and phenanthridine-6-one derivatives as pharmacological chaperones, i.e., small molecules that can rescue folding-defective phenotypes of mutated NPC1, opening up an avenue to develop chaperone therapy for Niemann-Pick disease type C. Here, we present an improved image-based screen for NPC1 chaperones and we describe its application for drug-repurposing screening.	Oxysterols	37-46	NPC intracellular cholesterol transporter 1	Homo sapiens	205-209	
12719428-6	2003	Moreover, we demonstrate that treatment with oxysterols reduces cholesterol in NPC mutants and is able to correct the NPC1I1061T phenotype, the most prevalent NPC1 disease genotype.	Oxysterols	45-55	NPC intracellular cholesterol transporter 1	Homo sapiens	118-122	
10751394-10	2000	Finally, we showed that the lysosomal cholesterol pool in NP-C cells was substantially and preferentially reduced by incubating cells with the oxysterols, 25-hydroxycholesterol and 7-ketocholesterol; these findings suggest a new pharmacological approach to the treatment of NP-C disease.	Oxysterols	143-153	NPC intracellular cholesterol transporter 1	Homo sapiens	58-62	
33315900-3	2020	We previously identified a series of oxysterol derivatives and phenanthridine-6-one derivatives as pharmacological chaperones, i.e., small molecules that can rescue folding-defective phenotypes of mutated NPC1, opening up an avenue to develop chaperone therapy for Niemann-Pick disease type C. Here, we present an improved image-based screen for NPC1 chaperones and we describe its application for drug-repurposing screening.	Oxysterols	37-46	NPC intracellular cholesterol transporter 1	Homo sapiens	346-350	
26239048-3	2015	We aimed to know the sensitivity and specificity of these biomarkers for the diagnosis of NPC compared with other diseases that can potentially lead to oxysterol alterations.	Oxysterols	152-161	NPC intracellular cholesterol transporter 1	Homo sapiens	90-93	
27147587-4	2016	The bile acids most elevated in the NPC subjects were identified as 3beta,5alpha,6beta-trihydroxycholanic acid and its glycine conjugate, which were shown to be metabolites of cholestane-3beta,5alpha,6beta-triol, an oxysterol elevated in NPC.	Oxysterols	216-225	NPC intracellular cholesterol transporter 1	Homo sapiens	36-39	
26733147-7	2016	Interestingly, in NP-C alone, we observed that plasma oxysterols correlate negatively with patient"s age and positively with serum total bilirubin, suggesting the potential relationship between oxysterol levels and hepatic disease status.	Oxysterols	54-63	NPC intracellular cholesterol transporter 1	Homo sapiens	18-22	
25095726-12	2015	CONCLUSION: Whilst acknowledging the limitations of this study, we conclude that screening ID children and adolescents with oxysterol tests compared to current practice for the diagnosis of NP-C is a dominant strategy with clinical and economic benefits.	Oxysterols	124-133	NPC intracellular cholesterol transporter 1	Homo sapiens	190-194	
24928400-5	2014	Here, we disclose detailed structure-activity relationships of oxysterol derivatives as pharmacological chaperones for NPC1(I1061T) mutant.	Oxysterols	63-72	NPC intracellular cholesterol transporter 1	Homo sapiens	119-123